1 November 2025 MBS pathology changes

This page provides information on the 1 November 2025 changes to MBS pathology items.

Page last updated: 15 October 2025

Effective 1 November 2025 the following amended pathology items will be listed on the Medicare Benefits Schedule (MBS):

    • Introduce a new MBS item for faecal calprotectin (FC) testing for symptomatic patients with Inflammatory Bowel Disease (IBD).
    • Introduce a new MBS item for dihydropyrimidine dehydrogenase (DPYD) genotyping to diagnose or predict fluoropyrimidine (FP)-induced toxicity.
    • Amend MBS items (73374, 73375, and 73376) for somatic gene testing of sarcomas to allow clinicians to choose which genes to test and to allow more frequent testing.
    • Introduce a new MBS item for Fibroblast growth factor 23 (FGF-23) testing for patients with a high pre-test probability of X-linked hypophosphatemia (XLH) to determine eligibility for burosumab on the Pharmaceutical Benefits Scheme (PBS).
    • Amend the Health Insurance (Pathology Services Table) Regulations 2020 for clinically indicated gross and histologic examination of placentas in perinatal deaths from current level 4 complexity tissue examinations to level 5 and level 6 complexity tissue examinations.
    • Amend non-small cell lung cancer (NSCLC) MBS items to restructure and refer to ‘relevant treatments’ under the Pharmaceutical Benefits Scheme (PBS) in a consistent manner.
Further information can be found in the factsheets below:

Factsheet
PDF and Word versions
New MBS item for faecal calprotectin testing

(Last updated:
 15 October 2025)
New Medicare Benefits Schedule item for dihydropyrimidine dehydrogenase (DPYD) genotyping

(Last updated: 15 October 2025)

Amendments to Medicare Benefits Schedule items for somatic gene testing for sarcoma

(Last updated: 15 October 2025)

New Medicare Benefits Schedule item for Fibroblast growth factor 23 (FGF-23) testing

(Last updated: 15 October 2025)

Amendments to Medicare Benefits Schedule for placental tissue examinations complexity levels

(Last updated: 15 October 2025)

Amendments to Medicare Benefits Schedule items for non-small cell lung cancer (NSCLC)

(Last updated: 15 October 2025)

In this section